---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-061522"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:49:19.426959+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# MindMed reports Phase 2b topline data for MM120 in GAD; gets FDA Breakthrough Therapy Designation

## Summary
- Phase 2b trial of MM120 (LSD) for Generalized Anxiety Disorder: full topline data released on March 7, 2024.
- FDA granted Breakthrough Therapy Designation for MM120 in GAD, accelerating development and review.
- Company hosted conference call to discuss results and ODT PK bridging study data.
- MM120 is a proprietary sublingual formulation of lysergide targeting anxiety disorders.

## SEC filing metadata
- accession: 0001193125-24-061522
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000119312524061522/0001193125-24-061522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000119312524061522/d788108d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-061522
- JSON: https://secwatch.observer/filing/0001193125-24-061522.json
- Plain text: https://secwatch.observer/filing/0001193125-24-061522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.